



Subtype-specific sirtuin expression signatures link mitochondrial–epigenetic networks to breast cancer survival

Zoltan Ungvari · Otília Menyhárt · Alberto Ocana · Andrea Lehoczki  ·
Monika Fekete · Giampaolo Bianchini · Balázs Győrffy

Received: 29 October 2025 / Accepted: 30 January 2026
© The Author(s) 2026

Abstract Sirtuins (SIRT1–SIRT7) are NAD⁺-dependent regulators of mitochondrial metabolism, chromatin remodeling, and stress resilience pathways—processes that are central to both aging biology and breast cancer (BC) heterogeneity. We systematically evaluated their prognostic and transcriptional patterns across molecular subtypes of BC. We constructed an integrated BC dataset comprising gene expression and survival data containing tumors

from 55 datasets. Prognostic associations with recurrence-free survival (RFS, $n=4384$) were evaluated by univariate Cox and Kaplan–Meier analyses using best cutoffs with FDR control, first for individual sirtuins and then for multigene combinations. Differential expression across normal, tumor, and metastatic tissues, as well as pairwise coexpression (Spearman's ρ), was assessed using the TNMplot platform. Among individual genes, SIRT3 showed the most consistent association with improved RFS across PAM50 subtypes. Multigene signatures outperformed individual

Zoltan Ungvari and Otília Menyhárt contributed equally to this work.

Z. Ungvari
Vascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

Z. Ungvari
International Training Program in Geroscience, Doctoral College, Health Sciences Division/Institute of Preventive Medicine and Public Health, Semmelweis University, Budapest, Hungary

O. Menyhárt · B. Győrffy
Department of Bioinformatics, Semmelweis University, 1094 Budapest, Hungary

O. Menyhárt · B. Győrffy
Cancer Biomarker Research Group, Institute of Molecular Life Sciences, Hungarian Research Network, Magyar Tudósok Körútja 2, 1117 Budapest, Hungary

O. Menyhárt · M. Fekete · B. Győrffy
Institute for Translational Research, Budapest, Hungary

A. Ocana
Experimental Therapeutics in Cancer Unit, Instituto de Investigación Sanitaria San Carlos (IdISSC), and CIBERONC, Madrid, Spain

A. Ocana
INTHEOS-CEU-START Laboratory, Facultad de Medicina, Universidad CEU San Pablo, 28668 Boadilla del Monte, Madrid, Spain

A. Lehoczki (✉) · M. Fekete
Institute of Preventive Medicine and Public Health, Semmelweis University, Budapest, Hungary
e-mail: Andrea.m.lehoczki@gmail.com

A. Lehoczki · M. Fekete · B. Győrffy
Fodor Center for Prevention and Healthy Aging, Semmelweis University, Budapest, Hungary

G. Bianchini
Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy

sirtuins and displayed clear subtype specificity. A three-gene panel (SIRT3+SIRT5+SIRT6) stratified risk in Luminal A ($p=8.1\text{e-}7$), Luminal B ($p=6.6\text{e-}6$), HER2-enriched ($p=1.0\text{e-}4$), and Basal-like BC ($p=3.8\text{e-}5$). In Basal-like tumors, the combination of SIRT3, SIRT6, and SIRT7 achieved the best performance ($p=2.6\text{e-}7$). Top-performing panels were not simple aggregates of individually significant genes, indicating synergistic, context-dependent effects. Expression analyses revealed concordant downregulation of SIRT3 and SIRT5 in tumors, accompanied by consistent upregulation of SIRT7. Coexpression analysis revealed disease-specific rewiring: tumors exhibited a reinforced axis linking SIRT3/SIRT5/SIRT6/SIRT2, and attenuation of SIRT1 and SIRT4 coupling. Distinct integrated sirtuin scores thus capture subtype-specific metabolic/epigenetic states and provide robust RFS stratification across BC subtypes. These findings highlight sirtuins as integrators of longevity pathways and tumor metabolism, suggesting therapeutically exploitable vulnerabilities along NAD⁺-dependent regulatory axes.

Keywords Sirtuins · Breast cancer · Prognostic model · Transcriptomic integration · Multigene signature · Coexpression network · Recurrence-free survival · Epigenetic regulation, Subtype-specific signatures · NAD⁺ metabolism · Gerooncology · Aging and cancer · Longevity genes · Aging–cancer interface · Mitochondrial signaling

Introduction

Breast cancer (BC) is among the most prevalent and heterogeneous malignancies worldwide, and its incidence rises steeply with age [1–3]. Aging is a significant risk factor for BC development, influencing not only tumor initiation but also disease progression, treatment response, and outcomes [1, 4, 5]. At the molecular level, aging is characterized by progressive metabolic, epigenetic, and transcriptional

reprogramming that diminishes cellular resilience and genomic stability⁶. Many of the same pathways that maintain metabolic homeostasis during youth—particularly those regulating redox balance, DNA repair, and mitochondrial function—are altered during tumorigenesis⁶. Understanding how molecular programs regulating cellular aging processes and organismal longevity intersect with breast cancer biology may therefore reveal mechanistic links between aging and malignancy and identify new targets for intervention [7–14].

Among the most extensively studied longevity effectors are the sirtuins (SIRT1–SIRT7), a family of NAD⁺-dependent deacylases and mono-ADP-ribosyltransferases that coordinate metabolic and stress-response pathways across cellular compartments [15–17]. By coupling enzymatic activity to NAD⁺ availability, sirtuins act as metabolic sensors that translate energetic status into adaptive gene expression programs [15–18]. Through this function, they promote mitochondrial biogenesis [13, 19, 20], maintain genomic integrity [21, 22], and modulate inflammation [23–26] and apoptosis [27]—processes central to both organismal aging and carcinogenesis. Loss or dysregulation of sirtuin activity has been implicated in multiple age-related diseases, including neurodegeneration [28–30] cardiovascular disorders [31–33] stroke [34], and cancer [10–13, 35–40].

Despite extensive preclinical work, the role of sirtuins in human breast cancer remains incompletely understood and context-dependent [7, 41–43–44, 45, 46, 814]. Individual members of the family have been described as both tumor suppressors and tumor promoters depending on molecular subtype, cellular context, and metabolic environment. For example, SIRT1 may repress oncogenic transcription factors [39] but can also enhance DNA repair and survival in malignant cells [47–51] SIRT3 maintains mitochondrial homeostasis and oxidative phosphorylation and is generally considered protective [52–58] while SIRT6 regulates cellular survival and genomic stability by facilitating DNA repair and repressing glycolytic gene expression [59–64]. In contrast, SIRT7, a nucleolar deacetylase involved in rRNA transcription, is often overexpressed in tumors and has been linked to poor differentiation and chemoresistance [65–79]. These divergent findings underscore the complexity of sirtuin regulation in cancer and

G. Bianchini
Vita-Salute San Raffaele University, Milan, Italy

B. Györfy
Institute of Transdisciplinary Discoveries, Medical School,
University of Pecs, Pecs 7624, Hungary

highlight the need for systematic, subtype-resolved analyses in large patient populations [64–80].

Breast cancer heterogeneity [81, 82]—reflected in intrinsic molecular subtypes (Luminal A, Luminal B, HER2-enriched, Basal-like, and Normal-like) [83]—is driven by distinct metabolic and epigenetic landscapes. Because sirtuins integrate these same dimensions of cellular physiology, their expression patterns and prognostic roles may vary substantially between subtypes [80]. However, prior studies have generally focused on single sirtuins in limited cohorts, precluding cross-subtype comparison and assessment of potential synergistic or compensatory relationships among family members. Given that sirtuins operate as an interconnected regulatory network, combinatorial analysis of their expression could yield a more comprehensive view of their collective impact on tumor behavior and patient outcomes.

To address these gaps, we conducted an integrative meta-analysis of sirtuin gene expression and prognostic significance across all major molecular subtypes of breast cancer. Using harmonized transcriptomic data from 55 independent cohorts encompassing 7830 tumors—including 4384 with recurrence-free survival information—we systematically assessed the associations of SIRT1–SIRT7 expression, individually and in combination, with clinical outcomes. We further evaluated sirtuin expression dynamics across normal breast tissue, primary tumors, and metastases, and mapped coexpression networks to identify disease-specific regulatory rewiring. This comprehensive approach aimed to uncover subtype-specific sirtuin signatures that reflect metabolic and epigenetic states within tumors and to explore how alterations in the sirtuin axis might link longevity pathways to breast cancer progression and recurrence.

Methods

Dataset identification and selection

A comprehensive search was conducted in the Gene Expression Omnibus (GEO) (<https://www.ncbi.nlm.nih.gov/geo/>) and the European Genome-Phenome Archive (EGA) repositories to retrieve publicly available transcriptomic datasets containing both gene expression profiles and associated clinical outcome data. Only datasets comprising a minimum of 30

patient samples were included to ensure adequate statistical power. To facilitate platform harmonization and cross-cohort integration, we restricted the analysis to datasets generated using the Affymetrix GPL96, GPL570, or GPL571 platforms. These platforms utilize an identical set of 22,277 probe sets, enabling consistent sensitivity, specificity, and dynamic range across studies due to their use of identical probe sequences.

Data normalization and quality control

All raw microarray data were processed using MAS5 normalization, selected for its strong performance in benchmark evaluations against RT-qPCR-validated datasets and its compatibility with single-sample normalization. To further minimize inter-study batch effects, we applied an additional scaling normalization, in which the mean expression of the shared 22,277 probe sets was standardized to a value of 1000 per array [84]. All normalized arrays were screened for duplication by comparing expression values across all samples. Identical profiles were considered duplicates, and in such cases, only the earliest published instance of the array was retained. Quality control was performed using five technical parameters: background intensity, raw *Q* values, percentage of present calls, presence of bioB/C/D spike-in controls, and the 3'/5' signal intensity ratio of housekeeping genes GAPDH and ACTB. Samples passing all five metrics or falling within the 95th percentile range for continuous parameters were classified as high quality [85]. Arrays failing one metric were flagged as outliers, while those failing two or more were considered biased and were excluded from downstream statistical analyses.

Univariate Cox regression

Breast cancer molecular subtypes (Luminal A, Luminal B, HER2-enriched, Basal-like, and Normal-like) were defined according to the PAM50 gene expression classifier, which stratifies tumors based on the relative expression of 50 intrinsic genes that capture estrogen receptor signaling, HER2 amplification, and proliferative activity [83]. To evaluate the prognostic value of individual sirtuin genes, univariate Cox proportional hazards regression analyses were performed on the expression levels of SIRT1 through SIRT7

across all major PAM50 breast cancer subtypes (Luminal A, Luminal B, HER2-enriched, Basal-like, and Normal-like) with the Kaplan–Meier plotter platform [86]. The endpoint analyzed was recurrence-free survival (RFS). For each gene and subtype, patients were dichotomized into high- and low-expression groups using the best cutoff method, which selects the optimal percentile threshold based on the lowest log-rank p value. To account for multiple tests, false discovery rate (FDR) values were calculated for each comparison [87, 88]. Based on statistical significance (p values and false discovery rates, or FDRs) and consistent directionality of hazard ratios, sirtuins with potential prognostic value were identified within each subtype. These results guided the subsequent combinatorial analysis, in which multigene sirtuin signatures—ranging from two to seven genes—were constructed and evaluated to identify the most prognostically informative subtype-specific combinations.

Gene expression differences across normal tissues, tumors, and metastatic samples

We compared the expression of select Sirtuin genes between normal tissues, tumors, and metastatic samples using the TNMplot webserver accessed at <https://tnmplot.com> [89], which aggregates GEO and TCGA datasets and provides interactive visualizations of differential expression.

Additionally, pairwise coexpression among the seven sirtuin genes (SIRT1–SIRT7) was quantified using Spearman rank correlation (ρ) on per-sample expression values obtained from TNMplot (GEO dataset). Correlations were computed separately for normal breast tissue and for breast tumors, without BC subtype stratification, to assess disease-associated network rewiring. Metastatic samples were excluded from the correlation analysis due to heterogeneity and limited statistical power.

Results

Database construction

The comprehensive, integrated breast cancer (BC) database comprised 7830 tumor samples collected from 55 independent datasets. Of these, 4384 samples included both RFS information and sirtuin

Table 1 Clinical and demographic characteristics of the investigated BC patient population

Category	Number of patients	Number of patients with sirtuin expression
Samples with RFS data	4934	4384
ER-positive	3499	2324
Tamoxifen-treated (subset of ER+)	1063	829
Aromatase inhibitor-treated (subset of ER+)	68	62
ER-negative	2168	977
Lymph node-negative	2829	2196
Lymph node-positive	2153	1307
Grade 1	576	364
Grade 2	1795	991
Grade 3	2053	1031
Age < 50 years	1957	1006
Age ≥ 50 years	2633	1538
Luminal A	2470	1656
Luminal B	2005	1208
Basal-like	1671	775
HER2-enriched	1080	648
Normal-like	309	97

gene expression data, forming the analytical cohort for this study. Within this cohort, 2324 tumors were estrogen receptor (ER)–positive and 977 were ER-negative. Among ER-positive patients, 829 were treated with tamoxifen only, and 62 patients were treated with aromatase inhibitors.

Clinical annotation further indicated 2196 lymph node-negative and 1307 lymph node-positive cases, as well as 364 grade 1, 991 grade 2, and 1031 grade 3 tumors. Regarding patient age, 1006 cases were diagnosed in patients under 50 years of age, while 1538 cases occurred in patients aged 50 years or older.

Based on PAM50 classification, Luminal A tumors represented the largest group (1656 patients, 37.8%), followed by Luminal B (1208 patients, 27.6%), Basal-like (775 patients, 17.2%), and HER2-enriched tumors (648 patients, 14.8%). Normal-like tumors were less common, comprising 97 patients (2.2%) (Table 1).

Univariate Cox regression


To assess the prognostic relevance of individual sirtuins, we performed univariate Cox proportional hazards regression analyses for SIRT1 through SIRT7 within each PAM50-defined BC subtype using RFS as the clinical endpoint. Among the seven genes tested, SIRT3 emerged as the most consistently significant prognostic marker, showing associations with RFS across all five subtypes (Fig. 1). SIRT6 also demonstrated broad prognostic value, being significant in Luminal B, HER2-enriched, Basal-like, and Normal-like breast cancer subtypes, while SIRT7 was prognostic in Basal-like and HER2-enriched breast tumor subtypes (Fig. 2). SIRT5 showed subtype-dependent effects, reaching significance only in Luminal B cancers (Fig. 2), whereas SIRT1, SIRT2, and SIRT4 did not demonstrate consistent prognostic associations. The detailed hazard ratios, confidence intervals, and p values for each gene and subtype are summarized in Table 2.

Prognostic value of integrated sirtuin signatures

We systematically evaluated the prognostic value of multigene sirtuin combinations for RFS across PAM50 BC subtypes by assembling panels from the top-performing individual sirtuins in each group. A robust, cross-subtype signal emerged: the SIRT3+SIRT5+SIRT6 signature was significantly associated with RFS in Luminal A ($p=8.1\text{e-}7$), Luminal B ($p=6.6\text{e-}6$), HER2-enriched ($p=1.0\text{e-}4$), and Basal-like ($p=3.8\text{e-}5$) tumors, but not in Normal-like disease. The four-gene panel, comprising SIRT3, SIRT5, SIRT6, and SIRT7, demonstrated similarly consistent prognostic relevance (Table 3). By subtype, the clearest effect in Luminal A was related to the combination of SIRT3+SIRT5+SIRT6 ($p=8.1\text{e-}7$; Fig. 3A). In Luminal B, several combinations performed exceptionally, including SIRT3+SIRT5+SIRT6+SIRT7 ($p=8.8\text{e-}8$; Fig. 3B) and SIRT2+SIRT3+SIRT5+SIRT6+SIRT7 ($p=2.6\text{e-}7$). For HER2-enriched tumors, SIRT3+SIRT5+SIRT6+SIRT7 yielded the strongest association ($p=2.8\text{e-}7$; Fig. 3C); notably, most combinations that included SIRT3 and SIRT6 were significant ($\text{FDR} \leq 10\%$). In Basal-like disease, SIRT3+SIRT6+SIRT7

stood out ($p=2.6\text{e-}7$; Fig. 3D), followed by SIRT2+SIRT3+SIRT5+SIRT6+SIRT7 ($p=3.2\text{e-}7$). Normal-like tumors yielded fewer robust signals, although SIRT3+SIRT6+SIRT7 ($p=8.0\text{e-}4$) and SIRT3+SIRT6 ($p=9.0\text{e-}4$) showed significant associations (Table 3). These findings support the hypothesis that specific combinations of sirtuin genes, particularly those involving SIRT3 and SIRT6, may serve as robust subtype-specific prognostic biomarkers. Our results identify SIRT3 as a central node in multiple prognostic combinations, supporting further investigation into the SIRT3-driven regulatory axis in breast cancer progression. The reproducibility of these signatures across multiple subtypes also suggests shared mechanisms of action in tumor recurrence, possibly reflecting metabolic vulnerabilities or epigenetic states governed by sirtuin activity. Importantly, the prognostic advantage of these multigene signatures does not simply reflect the additive effects of individually significant genes, but rather the ability of integrated models to capture emergent, network-level behavior arising from coordinated metabolic and epigenetic regulation.

An important observation is that the strongest subtype-specific combinations were not always composed exclusively of individually significant genes. For example, in Luminal A and Normal-like tumors, the best-performing signatures (SIRT3+SIRT5+SIRT6 and SIRT3+SIRT6+SIRT7, respectively) contained one or more sirtuins that did not reach statistical significance after FDR correction when assessed individually. Similarly, in HER2-enriched cancers, SIRT5 showed no prognostic value alone, yet its inclusion with SIRT3, SIRT6, and SIRT7 yielded one of the most robust multigene signatures. In contrast, the Basal-like subtype presented the most coherent pattern, where all three genes of the optimal combination (SIRT3, SIRT6, and SIRT7) were also independently significant. These findings illustrate that prognostic information can emerge through synergistic interactions between genes, and that multigene signatures capture biologically meaningful dependencies that are not apparent at the single-gene level. This underscores the value of combinatorial, network-based approaches in biomarker discovery, particularly for pathways such as sirtuin signaling that operate through coordinated metabolic–epigenetic regulation.



◀**Fig. 1** Prognostic impact of the expression of SIRT3 on recurrence-free survival (RFS) by BC subtypes. Kaplan–Meier plots compare patients with high (red) versus low (black) expression of signatures. High expression is associated with improved RFS, as indicated by hazard ratios (HR), 95% confidence intervals (CI), and log-rank *P* value shown in the plot. The number of patients at risk at selected time points is displayed below the curves

Sirtuin expression during tumor progression

Of the seven sirtuins, only SIRT3, SIRT5, SIRT6, and SIRT7 showed prognostic relevance in our survival analyses. We therefore examined their expression across normal breast tissue, primary tumors, and metastases using TNMplot. Across cohorts, the sirtuins show distinct—and partly divergent—expression patterns. SIRT3 gene expression drops from normal tissue to primary tumors and metastases, with significantly lower levels in tumors in both GEO (Kruskal–Wallis $p=7.22\text{e-}18$) and TCGA datasets ($p=5.12\text{e-}4$; Fig. 4A). SIRT5 follows a similar downward trajectory from normal to tumor to metastasis, reaching strong significance in GEO ($p=1.57\text{e-}38$) and exhibiting a parallel trend in TCGA ($p=0.08$; Fig. 4B). For SIRT6, gene expression is reduced in metastases compared to normal tissues or tumors in the GEO ($p=1.24\text{e-}16$) but increased in tumors in the TCGA dataset ($p=3.07\text{e-}20$; Fig.). In contrast, SIRT7 is consistently elevated in tumors compared to normal samples in both datasets (GEO: $p=1.43\text{e-}20$; TCGA: $p=2.02\text{e-}22$). Collectively, these results indicate concordant downregulation of SIRT3 and SIRT5 in tumors, robust upregulation of SIRT7, and a dataset-dependent behavior for SIRT6.

A significant limitation is that TNMplot does not provide subtype-resolved comparisons. In our survival analyses, favorable associations of sirtuin expression were observed in specific molecular subtypes, indicating context-dependent effects; therefore, these bulk differences cannot be directly mapped to PAM50 groups. The apparent tension between SIRT7 (or SIRT6 in the TCGA data) overexpression in tumors and its association with better outcomes likely reflects this heterogeneity and warrants further mechanistic investigation.

Notably, SIRT3 demonstrated internal consistency across platforms and endpoints, with expression declining from normal to primary to metastatic tissue. Higher tumor SIRT3 levels were associated

with improved relapse-free survival, suggesting that preservation of SIRT3-linked mitochondrial/oxidative programs marks a less aggressive, more treatment-responsive phenotype.

Coordinated sirtuin expression in normal tissues and BC samples

In normal breast tissue, sirtuins form a broadly coordinated network, with the tightest links between SIRT6 and SIRT5, as well as between SIRT6 and SIRT2. SIRT1 is positively aligned with this module, while SIRT3 is only modestly connected (Fig. 5A).

Nevertheless, in breast tumors, this architecture is rewired into a cancer-specific module centered on SIRT3/SIRT5/SIRT6 (and often SIRT2), suggesting a shared metabolic/stress-response program. Two major shifts highlight tumor-specific regulations: SIRT3 strengthens its ties and transitions from a peripheral role in normal tissues to an integrated hub in breast tumors, while SIRT1 shifts from positive coupling in normal tissues to weak negative associations in BC. In parallel, SIRT4 becomes largely decoupled in tumors, and the SIRT7–SIRT3 link becomes attenuated (Fig. 5B). Together, these changes indicate disease-associated reorganization of the sirtuin program, providing a mechanistic rationale for why multigene signatures built around the SIRT3/SIRT5/SIRT6/SIRT2 axis outperform single-gene markers. Because TNMplot provides bulk tissue comparisons without stratification by molecular subtype, these analyses reflect aggregate expression trends and do not capture subtype-specific expression dynamics, which may account for apparent discrepancies between expression level changes and survival associations for certain sirtuins, such as SIRT7.

Discussion

Sirtuins (SIRT1–SIRT7) are evolutionarily conserved NAD⁺-dependent enzymes that regulate chromatin structure, mitochondrial metabolism, and cellular stress resilience [15, 18]. Originally discovered as longevity genes in lower organisms [90–92], they orchestrate many of the biological processes that deteriorate with age—including genomic stability [22], cellular stress resistance pathways [93, 94], mitochondrial metabolism [7, 36, 95], and redox




Fig. 2 Prognostic impact of SIRT3, SIRT5, SIRT6, and SIRT7 expression across breast cancer subtypes. Forest plots display hazard ratios (HRs) with 95% confidence intervals (CIs) for recurrence-free survival (RFS) derived from Cox proportional hazards models, shown for all cases and stratified by intrinsic

subtype. An HR < 1 indicates that higher gene expression is associated with a reduced risk of recurrence (favorable prognosis), whereas an HR > 1 indicates increased risk (unfavorable prognosis). The vertical dashed line marks HR = 1 (no effect)

homeostasis [33]. Because cancer is fundamentally an age-related disease that emerges as these homeostatic networks deteriorate, alterations in sirtuin expression and activity may mark—or even drive—the transition from adaptive to maladaptive stress responses within the aging tissue microenvironment, thereby fostering carcinogenesis, tumor progression, and metastasis.

In this study, we conducted a large-scale integrative analysis of sirtuin expression and prognostic relevance across molecular subtypes of breast cancer. By combining data from 55 independent transcriptomic

cohorts, we identified reproducible multigene sirtuin signatures with strong predictive value for recurrence-free survival. Among individual genes, SIRT3 consistently emerged as the most favorable prognostic marker [54–56, 80], while combinations including SIRT3, SIRT5, SIRT6, and SIRT7 [73, 96] provided maximal predictive power across Luminal A/B, HER2-enriched, and Basal-like tumors. These findings indicate that a coordinated metabolic–epigenetic network regulated by the sirtuin family collectively underlies the observed prognostic associations and

Table 2 Prognostic significance of individual sirtuin genes across PAM50 BC subtypes based on recurrence-free survival (RFS). Univariate Cox proportional hazards regression was performed for each sirtuin gene (SIRT1–SIRT7) separately within the five major B subtypes (Luminal A, Luminal B, HER2-enriched, Basal-like, and Normal-like). For each analysis, the optimal expression cutoff was determined using the best cutoff method, and corresponding *p* values and false discovery rates (FDR) are reported. Bold values indicate statistical significance (FDR ≤ 10%)

Sirtuins	Luminal A HR (95% CI)	Luminal A (<i>p</i> , FDR)	Luminal B HR (95% CI)	Luminal B (<i>p</i> , FDR)	HER2- enriched HR (95% CI)	HER2-enriched (<i>p</i> , FDR)	Basal HR (95% CI)	Basal (<i>p</i> , FDR)	Normal-like HR (95% CI)	Normal-like (<i>p</i> , FDR)
SIRT1	0.86 (0.66–1.12)	0.2681, 100%	0.79 (0.65–0.96)	0.0178, > 50%	1.14 (0.88–1.47)	0.3298, 100%	1.13 (0.88–1.44)	0.3407, 100%	2.03 (0.95–4.31)	0.0606, 100%
SIRT2	0.77 (0.6–0.97)	0.0284, > 50%	0.75 (0.61–0.92)	0.0051, 50%	0.76 (0.58–1.00)	0.05, > 50%	0.74 (0.58–0.96)	0.0208, > 50%	0.6 (0.25–1.48)	0.2664, 100%
SIRT3	0.63 (0.5–0.79)	6.3e-5, 1%	0.72 (0.6–0.87)	0.0005, 5%	0.64 (0.5–0.82)	0.0004, 5%	0.67 (0.53–0.85)	0.0008, 10%	0.29 (0.13–0.67)	0.0019, 10%
SIRT4	0.8 (0.64–0.99)	0.0376, > 50%	0.86 (0.72–1.03)	0.1117, 100%	1.24 (0.92–1.68)	0.1563, 100%	1.31 (0.99–1.73)	0.0546, 100%	0.49 (0.2–1.21)	0.1166, 100%
SIRT5	0.67 (0.46–0.97)	0.0347, > 50%	0.57 (0.42–0.77)	0.0002, 2%	1.28 (0.91–1.8)	0.1631, 100%	1.24 (0.88–1.76)	0.2215, 100%	0.28 (0.08–0.99)	0.0343, 50%
SIRT6	0.76 (0.6–0.96)	0.0194, > 50%	0.71 (0.58–0.86)	0.0006, 5%	0.61 (0.47–0.81)	0.0004, 5%	0.64 (0.50–0.81)	0.0002, 2%	0.28 (0.13–0.61)	0.0007, 3%
SIRT7	1.12 (0.9–1.4)	0.3052, 100%	0.76 (0.63–0.92)	0.0038, 50%	0.6 (0.46–0.78)	0.0001, 1%	0.54 (0.41–0.71)	6.9e-6, 1%	0.5 (0.23–1.1)	0.0774, 100%

Table 3 Prognostic significance of the integrated sirtuin score across PAM50 breast cancer subtypes based on recurrence-free survival (RFS). Bold values indicate the most potent sirtuin combination for each BC subtype. *FDR*, false discovery rate

Integrated sirtuin score	Luminal A (<i>p</i> values, <i>FDR</i>)	Luminal B (<i>p</i> values, <i>FDR</i>)	HER2-enriched (<i>p</i> values, <i>FDR</i>)	Basal-like (<i>p</i> values, <i>FDR</i>)	Normal-like (<i>p</i> values, <i>FDR</i>)
SIRT2+SIRT3+SIRT6	0.0229, > 50%	0.0003, 3%	0.0012, 10%	0.0001, 1%	0.0021, 10%
SIRT3+SIRT5+SIRT6	8.1e-7, 1%	6.6e-6, 1%	0.0001, 1%	3.8e-5, 1%	0.1703, 100%
SIRT3+SIRT6+SIRT7	0.1131, 100%	4.9e-7, 1%	0.0004, 5%	2.6e-7, 1%	0.0008, 5%
SIRT2+SIRT3+SIRT5+SIRT6	0.0002, 2%	1.9e-6, 1%	3.8e-5, 1%	7.3e-7, 1%	0.2323, 100%
SIRT2+SIRT3+SIRT6+SIRT7	0.0391, > 50%	4.0e-5, 1%	0.0013, 10%	1.2e-6, 1%	0.0054, 20%
All 7 sirtuins	0.0003, 3%	2.2e-6, 1%	2.4e-5, 1%	0.0005, 5%	0.3659, 100%
SIRT2+SIRT3+SIRT5+SIRT6+SIRT7	0.0004, 3%	2.6e-7, 1%	1.9e-6, 1%	3.2e-7, 1%	0.2244, 100%
SIRT3+SIRT5+SIRT6+SIRT7	0.0001, 1%	8.8e-8, 1%	2.8e-7, 1%	3.8e-6, 1%	0.0912, 100%
SIRT3+SIRT6	0.0061, 50%	0.0013, 10%	1.8e-6, 1%	9.9e-7, 1%	0.0009, 5%

that its integrity differs between breast cancer subtypes. Importantly, the sirtuin-based signatures identified here are not intended to replace clinically validated assays such as Oncotype DX or MammaPrint. Rather, they provide complementary, pathway-level biological insight by capturing mitochondrial and epigenetic fitness, dimensions that are not explicitly represented in current prognostic tools. Future studies integrating sirtuin signatures with established clinical predictors will be required to assess their additive prognostic value.

Breast cancer represents a highly heterogeneous disease composed of molecularly distinct subtypes, each defined by unique transcriptional, metabolic, and epigenetic architectures [97]. These intrinsic subtypes differ markedly in their dependence on estrogen signaling, proliferative rate, and metabolic reprogramming, ranging from the oxidative, hormone-responsive Luminal tumors to the glycolytic, aggressive Basal-like phenotype [81–83]. Our analysis demonstrates that sirtuin expression mirrors this diversity: distinct combinations of SIRT3, SIRT5, SIRT6, and SIRT7 provide maximal prognostic power within each subtype, indicating that sirtuin activity is embedded in the metabolic characteristics of individual tumor classes. The consistent prognostic value of SIRT3 and SIRT6 across subtypes points to a shared mitochondrial–epigenetic axis that maintains redox balance and chromatin stability, whereas differences in the contribution of other sirtuins (such as SIRT7 [73] in Basal-like and HER2-enriched tumors) reflect subtype-specific patterns of metabolic adaptation and proliferative demand. These findings highlight that

sirtuin signatures not only stratify prognosis but also capture the underlying biological heterogeneity of breast cancer.

The biological functions of sirtuins provide a mechanistic rationale for their prognostic value. As NAD⁺-dependent deacetylases, they act as metabolic sensors linking cellular energy status to genome stability, mitochondrial function, and stress resistance—core processes at the intersection of aging and cancer [40, 98–101]. SIRT1, SIRT3, and SIRT6 suppress oncogenic transformation by promoting DNA repair, maintaining mitochondrial integrity, and repressing inflammatory or glycolytic pathways [102–106]. Conversely, under nutrient limitation or oxidative stress, sirtuins can enhance cancer cell survival by improving metabolic flexibility and apoptosis resistance [107–109]. This duality exemplifies the principle of antagonistic pleiotropy: mechanisms that preserve cellular fitness and longevity under physiological conditions may, in a different context, facilitate tumor persistence. Among sirtuin family members, SIRT3 appears central to this balance. As the principal mitochondrial deacetylase, SIRT3 regulates oxidative phosphorylation [110], detoxification of reactive oxygen species [111–114], and intrinsic apoptotic signaling. Loss of SIRT3 destabilizes mitochondrial DNA and promotes a glycolytic, Warburg-like metabolic phenotype—hallmarks of malignant transformation [115–118]. SIRT6 complements these functions by maintaining chromatin stability and repressing glycolytic and inflammatory gene expression, further supporting its tumor-suppressive role [119–122]. The coordinated activity of SIRT3, SIRT5, and SIRT6




Fig. 3 Prognostic impact of integrated sirtuin scores: high expression of the best-performing sirtuin combinations was associated with improved RFS and out-performed any single sirtuin marker in PAM50 BC subtypes. **A** Luminal A—SIRT3+SIRT5+SIRT6. **B**

Luminal B—SIRT3+SIRT5+SIRT6+SIRT7. **C** HER2-enriched—SIRT3+SIRT5+SIRT6+SIRT7. **D** Basal—SIRT3+SIRT6+SIRT7. Numbers at risk are shown beneath each plot. Abbreviations: HR, hazard ratio




Fig. 4 SIRT3/5/6 expressions across normal, primary tumor, and metastatic tissue samples in the GEO and TCGA datasets. Violin plots with median and interquartile range compare gene expression distributions across normal breast tissues, primary tumors, and metastatic samples. *P* values are from Kruskal–Wallis tests across the three groups. **A** SIRT3 expression

declines from normal to tumor and metastatic tissue in both cohorts. **B** SIRT5 shows a similar downward trend. **C** SIRT6 patterns diverge by cohort: expression is lower in tumors vs. normal samples in the GEO dataset, while higher in tumors in the TCGA dataset. Abbreviations: GEO, Gene Expression Omnibus; TCGA, The Cancer Genome Atlas




Fig. 5 Sirtuin coexpression (SIRT1–SIRT7) quantified by Spearman rank correlations (ρ) using TNMplot (GEO datasets). **A** In normal breast tissue, sirtuins form a broadly coordinated network centered on SIRT6, with particularly strong coexpression with SIRT5 and SIRT2. **B** In breast cancer, the

network is rewired: SIRT3, SIRT5, SIRT6, and SIRT2 remain tightly coexpressed, whereas SIRT1 shifts toward weak negative relationships, and SIRT4 becomes mainly uncoupled. Tiles report Spearman's ρ ; the color scale indicates the strength of correlation

thus preserves mitochondrial and epigenetic homeostasis, consistent with our observation that tumors expressing these genes exhibit a less aggressive phenotype and superior recurrence-free survival. While no new experimental validation was performed as part of this study, the recurrent identification of a SIRT3–SIRT5–SIRT6 axis across molecular subtypes highlights clear candidates for functional follow-up. Targeted perturbation of these sirtuins in subtype-specific breast cancer models will be essential to establish causality, delineate mechanistic dependencies, and assess therapeutic relevance.

Expression analyses across normal, primary, and metastatic samples revealed a clear pattern: SIRT3 and SIRT5 are downregulated in tumors, consistent with the loss of mitochondrial quality control and redox homeostasis, whereas SIRT7 is upregulated, likely reflecting increased ribosomal biogenesis and protein synthesis demand in proliferating cells [123]. Coexpression network analyses showed disease-specific rewiring of the sirtuin interactome, with SIRT3 shifting from a peripheral node in normal tissue to a central hub in tumors, linking SIRT5, SIRT6, and SIRT2 into a metabolic–stress response module. This architectural reorganization suggests that tumor cells selectively preserve components of

longevity-associated metabolic pathways to sustain survival under oxidative and energetic stress.

The feasibility of pharmacologically or nutritionally modulating sirtuin activity is supported by growing experimental evidence. Several small-molecule sirtuin activators have been developed¹²⁴. In vitro, these compounds enhance mitochondrial biogenesis, DNA repair, and cell survival under oxidative stress, and in animal models they extend lifespan or delay age-related decline. In cancer settings, activation of SIRT1 [125, 126], SIRT3, or SIRT6 [124] can inhibit cell proliferation and tumor growth by restoring oxidative metabolism and reducing ROS-driven genomic instability, while inhibition of SIRT2 or SIRT7 exerts antiproliferative effects in breast, colorectal and prostate cancer cells [127]. In vivo, SIRT3 activation reduces mammary tumorigenesis, whereas SIRT6 overexpression limits metastasis by suppressing glycolysis [8, 128, 130].

Clinical translation remains at an early stage. Beyond direct pharmacologic modulators, NAD⁺ boosters such as nicotinamide mononucleotide (NMN), NR, or niacin indirectly enhance sirtuin activity and are under investigation in clinical studies for metabolic and neurodegenerative disorders. Data in oncology are still exploratory, but these findings

suggest potential for sirtuin-targeted adjuvant therapies that restore mitochondrial function and reduce treatment-related metabolic stress. Increasing NAD⁺ availability might modulate early carcinogenic processes, particularly in the initiation and prevention phases, via support for DNA repair, maintenance of genomic stability, and improved cellular energetics [131]. However, care is warranted, as elevated NAD⁺ and sirtuin activity can have context-dependent, even adverse, effects on established tumors [132]. Lifestyle interventions, including time-restricted eating, regular physical activity, and plant-based diets rich in polyphenols, may naturally activate sirtuin pathways via increased NAD⁺ availability and AMPK signaling. Such physiological activators may confer metabolic resilience that not only delays aging but also mitigates cancer risk and recurrence, linking lifestyle, longevity pathways, and oncologic outcomes.

Despite its scale and reproducibility, this study has several limitations. It relies primarily on transcriptomic data, which may not fully reflect post-translational regulation, enzymatic activity, or subcellular localization of sirtuins. Clinical heterogeneity across cohorts, including differences in treatment regimens, menopausal status, and comorbidities, could not be fully controlled. Although aging is central to the biological framework of this study, age information was not consistently available as a continuous variable across all datasets, precluding linear modeling of age-dependent expression changes. Future analyses in harmonized cohorts with detailed age metadata will be necessary to characterize longitudinal sirtuin trajectories during aging. Moreover, the analyses are correlative in nature, and functional studies will be required to establish causal links between specific sirtuins and tumor aggressiveness. Survival analyses were based on univariate Cox regression models, as key clinicopathologic covariates such as tumor grade, nodal status, and treatment information were not uniformly available across all cohorts. Consequently, the present findings demonstrate prognostic association rather than independent prognostic value, and multivariable validation in well-annotated clinical datasets will be necessary. In addition, molecular subtype classification based on mRNA expression may introduce residual variability, and systemic modulators of sirtuin function, including NAD⁺ metabolism and inflammation, were not directly assessed. Consistent with this limitation, genes involved in

NAD⁺ biosynthesis and salvage pathways were not uniformly represented across platforms, restricting integrative analysis of NAD⁺–sirtuin coupling. Incorporation of NAD⁺ metabolic profiling in future multi-omics studies will therefore be critical for defining functional sirtuin activity in cancer. Because this meta-analysis integrates all available Affymetrix-based cohorts meeting inclusion criteria, an independent external validation cohort was not available. Nevertheless, the consistency of results across 55 independent datasets provides strong evidence of robustness, while prospective validation remains an important next step. Despite these limitations, the strength of our meta-analytic approach lies in its statistical power and reproducibility across diverse cohorts, providing compelling evidence that sirtuin expression networks capture clinically meaningful biological variation in breast cancer. Future studies integrating transcriptomic, proteomic, and metabolomic data will be essential to delineate sirtuin-regulated metabolic fluxes within tumors and their microenvironments. Given the emergence of pharmacologic and nutritional sirtuin modulators, these findings support further exploration of sirtuin targeting as an adjuvant strategy in breast cancer prevention and survivorship—particularly in older patients, where age-related decline in NAD⁺ metabolism may exacerbate disease progression and therapy-related toxicity.

In summary, distinct sirtuin expression signatures capture subtype-specific metabolic and epigenetic states in breast cancer. Beyond their prognostic value, these signatures reflect fundamental aspects of the aging–cancer interface. Enhancing sirtuin activity—through pharmacologic, metabolic, or lifestyle interventions—offers a promising avenue for aligning cancer prevention with healthy aging strategies.

Acknowledgements The 5.0 version of ChatGPT, developed by OpenAI, and the Claude 3.5 Sonnet, developed by Anthropic, were used as language tools to refine our writing and enhance the clarity of our work.

Author contribution ZU, OM, AL, MF, and BG contributed to the study conception and design. Statistical analyses were conducted by OM, AL, and BG. The manuscript was drafted by ZU, OM, AL, MF, and BG. AO and GB provided critical revisions for intellectual content. Figures were prepared by OM, AL, and BG. All authors reviewed, edited, and approved the final manuscript.

Funding Open access funding provided by Semmelweis University. This project was supported by the National Research, Development, and Innovation Office (EIPROPER, 2024-1.2.2-ERA_NET-2024-00015). O.M. was supported by the Janos Bolyai Scholarship of the Hungarian Academy of Sciences and the Hungarian Scientific Research Fund (OTKA FK147194). The computational infrastructure of A5 Genetics Ltd (Kutaso, Hungary) was used for the study. The support of ELIXIR Hungary (www.bioinformatics.hu) is acknowledged. This work was supported by TKP2021-NKTA-47, implemented with the support provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the TKP2021-NKTA funding scheme; by funding through the National Cardiovascular Laboratory Program (RRF-2.3.1-21-2022-00003), the Mission-driven National Cardiovascular Laboratory Program, by the ADVANCED-151053 and 2015-1.2.1.-HU-RIZONT-2-25-00016 (INNOBRAIN) grants and by the National Laboratory for Drug Research and Development (PharmaLab, RRF-2.3.1-21-2022-00015) provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund; by the Semmelweis Momentum Programme; Project no. 135784 implemented with the support provided from the National Research, Development and Innovation Fund of Hungary, financed under the K20 funding scheme and the European University for Well-Being (EUniWell) program (grant agreement number: 101004093/EUniWell/EAC-A02-2019/EAC-A02-2019-1). The funding sources had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

Declarations

Ethics approval and consent to participate NA.

Consent for publication NA.

Competing interests Dr. Balázs Györfly serves as Associate Editor for *GeroScience*. Dr. Zoltan Ungvari serves as Editor-in-Chief for *GeroScience*.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. *Nat Med*. 2025. <https://doi.org/10.1038/s41591-025-03502-3>.
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin*. 2022;72:7–33. <https://doi.org/10.3322/caac.21708>.
- Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. *Breast*. 2022;66:15–23. <https://doi.org/10.1016/j.breast.2022.08.010>.
- Kresovich JK, Xu Z, O'Brien KM, Weinberg CR, Sandler DP, Taylor JA. Methylation-based biological age and breast cancer risk. *J Natl Cancer Inst*. 2019;111:1051–8. <https://doi.org/10.1093/jnci/djz020>.
- Saez-Freire MDM, Blanco-Gomez A, Castillo-Lluya S, Gomez-Vecino A, Galvis-Jimenez JM, Martin-Seisdedos C, et al. The biological age linked to oxidative stress modifies breast cancer aggressiveness. *Free Radic Biol Med*. 2018;120:133–46. <https://doi.org/10.1016/j.freeradbiomed.2018.03.012>.
- Lopez-Otin C, Pietrocola F, Roiz-Valle D, Galluzzi L, Kroemer G. Meta-hallmarks of aging and cancer. *Cell Metab*. 2023;35:12–35. <https://doi.org/10.1016/j.cmet.2022.11.001>.
- Tharayil JS, Kandettu A, Chakrabarty S. The curious case of mitochondrial sirtuin in rewiring breast cancer metabolism: mr hyde or Dr Jekyll? *Biochim Biophys Acta Mol Basis Dis*. 2025;1871:167691. <https://doi.org/10.1016/j.bbadis.2025.167691>.
- Sharma D, Panchaksaram M, Muniyan R. Advancements in understanding the role and mechanism of sirtuin family (SIRT1-7) in breast cancer management. *Biochem Pharmacol*. 2025;232:116743. <https://doi.org/10.1016/j.bcp.2025.116743>.
- Ullah A, Waqas M, Halim SA, Daud M, Jan A, Khan A, et al. Sirtuin 1 inhibition: a promising avenue to suppress cancer progression through small inhibitors design. *J Biomol Struct Dyn*. 2024;42:9825–41. <https://doi.org/10.1080/07391102.2023.2252898>.
- Xiao F, Hu B, Si Z, Yang H, Xie J. Sirtuin 6 is a negative regulator of the anti-tumor function of natural killer cells in murine inflammatory colorectal cancer. *Mol Immunol*. 2023;158:68–78. <https://doi.org/10.1016/j.molimm.2023.04.011>.
- Raghu S, Prabhaskar AB, Shivaniah B, Tripathi E, Sundaresan NR. Sirtuin 6 is a critical epigenetic regulator of cancer. *Subcell Biochem*. 2022;100:337–60. https://doi.org/10.1007/978-3-031-07634-3_10.
- Mao L, Hong X, Xu L, Wang X, Liu J, Wang H, et al. Sirtuin 4 inhibits prostate cancer progression and metastasis by modulating p21 nuclear translocation and glutamate dehydrogenase 1 ADP-ribosylation. *J Oncol*. 2022;2022:5498743. <https://doi.org/10.1155/2022/5498743>.
- Torrens-Mas M, Hernandez-Lopez R, Pons DG, Roca P, Oliver J, Sastre-Serra J. Sirtuin 3 silencing impairs

- mitochondrial biogenesis and metabolism in colon cancer cells. *Am J Physiol Cell Physiol.* 2019;317:C398–404. <https://doi.org/10.1152/ajpcell.00112.2019>.
14. Latifkar A, Ling L, Hingorani A, Johansen E, Clement A, Zhang X, et al. Loss of sirtuin 1 alters the secretome of breast cancer cells by impairing lysosomal integrity. *Dev Cell.* 2019;49:393–408 e397. <https://doi.org/10.1016/j.devcel.2019.03.011>.
 15. Imai SI, Guarente L. It takes two to tango: NAD(+) and sirtuins in aging/longevity control. *NPJ Aging Mech Dis.* 2016;2:16017. <https://doi.org/10.1038/npjamd.2016.17>.
 16. Bonkowski MS, Sinclair DA. Slowing ageing by design: the rise of NAD(+) and sirtuin-activating compounds. *Nat Rev Mol Cell Biol.* 2016;17:679–90. <https://doi.org/10.1038/nrm.2016.93>.
 17. Satoh A, Imai S. Systemic regulation of mammalian ageing and longevity by brain sirtuins. *Nat Commun.* 2014;5:4211. <https://doi.org/10.1038/ncomms5211>.
 18. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. *Trends Cell Biol.* 2014;24:464–71. <https://doi.org/10.1016/j.tcb.2014.04.002>.
 19. Li H, Cai Z. SIRT3 regulates mitochondrial biogenesis in aging-related diseases. *J Biomed Res.* 2022;37:77–88. <https://doi.org/10.7555/JBR.36.20220078>.
 20. Yuan Y, Cruzat VF, Newsholme P, Cheng J, Chen Y, Lu Y. Regulation of SIRT1 in aging: roles in mitochondrial function and biogenesis. *Mech Ageing Dev.* 2016;155:10–21. <https://doi.org/10.1016/j.mad.2016.02.003>.
 21. Copp ME, Shine J, Brown HL, Nimmala KR, Hansen OB, Chubinskaya S, et al. Sirtuin 6 activation rescues the age-related decline in DNA damage repair in primary human chondrocytes. *Aging Albany NY.* 2023;15:13628–45. <https://doi.org/10.18632/aging.205394>.
 22. North BJ, Rosenberg MA, Jeganathan KB, Hafner AV, Michan S, Dai J, et al. SIRT2 induces the checkpoint kinase BubR1 to increase lifespan. *EMBO J.* 2014;33:1438–53. <https://doi.org/10.15252/embj.201386907>.
 23. Bae EJ, Park BH. Multiple roles of sirtuin 6 in adipose tissue inflammation. *Diabetes Metab J.* 2023;47:164–72. <https://doi.org/10.4093/dmj.2022.0270>.
 24. Chen X, Wei G, Li D, Fan Y, Zeng Y, Qian Z, et al. Sirtuin 1 alleviates microglia-induced inflammation by modulating the PGC-1 α /Nrf2 pathway after traumatic brain injury in male rats. *Brain Res Bull.* 2022;185:28–38. <https://doi.org/10.1016/j.brainresbull.2022.04.012>.
 25. Cao X, Wu Y, Hong H, Tian XY. Sirtuin 3 dependent and independent effects of NAD(+) to suppress vascular inflammation and improve endothelial function in mice. *Antioxidants.* 2022. <https://doi.org/10.3390/antiox11040706>.
 26. Wellman AS, Metukuri MR, Kazgan N, Xu X, Xu Q, Ren NSX, et al. Intestinal epithelial Sirtuin 1 regulates intestinal inflammation during aging in mice by altering the intestinal microbiota. *Gastroenterology.* 2017;153:772–86. <https://doi.org/10.1053/j.gastro.2017.05.022>.
 27. Liu L, Lu O, Li D, Tian Y, Liu Z, Wen Y, et al. Sirtuin 3 mitigates oxidative-stress-induced apoptosis in bovine mammary epithelial cells. *J Dairy Sci.* 2023;106:7266–80. <https://doi.org/10.3168/jds.2023-23366>.
 28. Cho SH, Chen JA, Sayed F, Ward ME, Gao F, Nguyen TA, et al. SIRT1 deficiency in microglia contributes to cognitive decline in aging and neurodegeneration via epigenetic regulation of IL-1 β . *J Neurosci.* 2015;35:807–18. <https://doi.org/10.1523/JNEUROSCI.2939-14.2015>.
 29. /2/807 [pii]
 30. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. *EMBO J.* 2007;26:3169–79.
 31. Herskovits AZ, Guarente L. Sirtuin deacetylases in neurodegenerative diseases of aging. *Cell Res.* 2013;23:746–58. <https://doi.org/10.1038/cr.2013.70>.
 32. Ota H, Akishita M, Eto M, Iijima K, Kaneki M, Ouchi Y. Sirt1 modulates premature senescence-like phenotype in human endothelial cells. *J Mol Cell Cardiol.* 2007;43:571–9. <https://doi.org/10.1016/j.yjmcc.2007.08.008>.
 33. D'Onofrio N, Servillo L, Balestrieri ML. SIRT1 and SIRT6 signaling pathways in cardiovascular disease protection. *Antioxid Redox Signal.* 2018;28:711–32. <https://doi.org/10.1089/ars.2017.7178>.
 34. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X, et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. *Circ Res.* 2007;100:1512–21.
 35. Petegnief V, Planas AM. SIRT1 regulation modulates stroke outcome. *Transl Stroke Res.* 2013;4:663–71. <https://doi.org/10.1007/s12975-013-0277-y>.
 36. Ansari A, Rahman MS, Saha SK, Saikot FK, Deep A, Kim KH. Function of the SIRT3 mitochondrial deacetylase in cellular physiology, cancer, and neurodegenerative disease. *Aging Cell.* 2017;16:4–16. <https://doi.org/10.1111/acer.12538>.
 37. Bringman-Rodenbarger LR, Guo AH, Lyssiotis CA, Lombard DB. Emerging roles for SIRT5 in metabolism and cancer. *Antioxid Redox Signal.* 2018;28:677–90. <https://doi.org/10.1089/ars.2017.7264>.
 38. Buhrmann C, Shayan P, Popper B, Goel A, Shakibaei M. Sirt1 is required for resveratrol-mediated chemopreventive effects in colorectal cancer cells. *Nutrients.* 2016;8:145. <https://doi.org/10.3390/nu8030145>.
 39. Chen L, Li M, Zhou H, Liu Y, Pang W, Ma T, et al. Sirtuin1 (SIRT1) is involved in the anticancer effect of black raspberry anthocyanins in colorectal cancer. *Eur J Nutr.* 2023;62:395–406. <https://doi.org/10.1007/s00394-022-02989-7>.
 40. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. *PLoS One.* 2008;3:e2020.
 41. Mostoslavsky R. DNA repair, insulin signaling and sirtuins: at the crossroads between cancer and aging. *Front Biosci.* 2008;13:6966–90.3203[pii].
 42. He S, He C, Yuan H, Xiong S, Xiao Z, Chen L. The SIRT 3 expression profile is associated with pathological and clinical outcomes in human breast cancer patients. *Cell Physiol Biochem.* 2014;34:2061–9. <https://doi.org/10.1159/000366401>.

43. Kaiser A, Kruger T, Eiselt G, Bechler J, Kniemeyer O, Huber O, et al. Identification of PARP-1, histone H1 and SIRT-1 as new regulators of breast cancer-related aromatase promoter 1.3/II. *Cells*. 2020. <https://doi.org/10.3390/cells9020427>.
44. Khalil M, Desouky EM, Khaliefa AK, Hozyen WG, Mohamed SS, Hasona NA. Insights into the crosstalk between miR-200a/lncRNA H-19 and IL-6/SIRT-1 axis in breast cancer. *J Interferon Cytokine Res*. 2024;44:191–7. <https://doi.org/10.1089/jir.2023.0216>.
45. Kim JE, Lou Z, Chen J. Interactions between DBC1 and SIRT 1 are deregulated in breast cancer cells. *Cell Cycle*. 2009;8:3784–5. <https://doi.org/10.4161/cc.8.22.10055>.
46. Sarma P, Bag I, Ramaiah MJ, Kamal A, Bhadra U, Pal Bhadra M. Bisindole-PBD regulates breast cancer cell proliferation via SIRT-p53 axis. *Cancer Biol Ther*. 2015;16:1486–501. <https://doi.org/10.1080/15384047.2015.1071731>.
47. Zhang J, Ye J, Zhu S, Han B, Liu B. Context-dependent role of SIRT3 in cancer. *Trends Pharmacol Sci*. 2024;45:173–90. <https://doi.org/10.1016/j.tips.2023.12.005>.
48. Wang C, Chen L, Hou X, Li Z, Kabra N, Ma Y, et al. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. *Nat Cell Biol*. 2006;8:1025–31.
49. Jeong J, Juhn K, Lee H, Kim SH, Min BH, Lee KM, et al. SIRT1 promotes DNA repair activity and deacetylation of Ku70. *Exp Mol Med*. 2007;39:8–13. <https://doi.org/10.1038/emmm.2007.2>.
50. Fan W, Luo J. SIRT1 regulates UV-induced DNA repair through deacetylating XPA. *Mol Cell*. 2010;39:247–58. <https://doi.org/10.1016/j.molcel.2010.07.006>.
51. Li L, Ye S, Yang M, Yu W, Fan Z, Zhang H, et al. SIRT1 downregulation enhances chemosensitivity and survival of adult T-cell leukemia-lymphoma cells by reducing DNA double-strand repair. *Oncol Rep*. 2015;34:2935–42. <https://doi.org/10.3892/or.2015.4287>.
52. Madabushi A, Hwang BJ, Jin J, Lu AL. Histone deacetylase SIRT1 modulates and deacetylates DNA base excision repair enzyme thymine DNA glycosylase. *Biochem J*. 2013;456:89–98. <https://doi.org/10.1042/BJ20130670>.
53. Jana S, Shang J, Hong JY, Fenwick MK, Puri R, Lu X, et al. A mitochondria-targeting SIRT3 inhibitor with activity against diffuse large B cell lymphoma. *J Med Chem*. 2024;67:15428–37. <https://doi.org/10.1021/acs.jmedchem.4c01053>.
54. Li T, Fan L, Jia Y, Xu C, Guo W, Wang Y, et al. Colorectal cancer cells with stably expressed SIRT3 demonstrate proliferating retardation by Wnt/beta-catenin cascade inactivation. *Clin Exp Pharmacol Physiol*. 2024;51:e13856. <https://doi.org/10.1111/1440-1681.13856>.
55. Ning L, Xie N. SIRT3 expression predicts overall survival and neoadjuvant chemosensitivity in Triple-Negative Breast Cancer. *Cancer Manag Res*. 2024;16:137–50. <https://doi.org/10.2147/CMAR.S445248>.
56. Jenkins EC, Chattopadhyay M, Germain D. Are the estrogen receptor and SIRT3 axes of the mitochondrial UPR key regulators of breast cancer sub-type determination according to age? *Aging Cancer*. 2021;2:75–81. <https://doi.org/10.1002/aac2.12035>.
57. Chen H, Zhang DM, Zhang ZP, Li MZ, Wu HF. SIRT3-mediated mitochondrial unfolded protein response weakens breast cancer sensitivity to cisplatin. *Genes & Genomics*. 2021;43:1433–44. <https://doi.org/10.1007/s13258-021-01145-5>.
58. Guo R, Li Y, Xue Y, Chen Y, Li J, Deng X, et al. SIRT3 increases cisplatin sensitivity of small-cell lung cancer through apoptosis. *Gene*. 2020;745:144629. <https://doi.org/10.1016/j.gene.2020.144629>.
59. Sawant Dessai A, Dominguez MP, Chen UI, Hasper J, Prechtel C, Yu C, et al. Transcriptional repression of SIRT3 potentiates mitochondrial aconitase activation to drive aggressive prostate cancer to the bone. *Cancer Res*. 2021;81:50–63. <https://doi.org/10.1158/0008-5472.CAN-20-1708>.
60. Abbotto E, Miro C, Piacente F, Salis A, Murolo M, Nappi A, et al. SIRT6 pharmacological inhibition delays skin cancer progression in the squamous cell carcinoma. *Biomed Pharmacother*. 2023;166:115326. <https://doi.org/10.1016/j.biopha.2023.115326>.
61. Bandopadhyay S, Prasad P, Ray U, Das Ghosh D, Roy SS. SIRT6 promotes mitochondrial fission and subsequent cellular invasion in ovarian cancer. *FEBS Open Bio*. 2022;12:1657–76. <https://doi.org/10.1002/2211-5463.13452>.
62. Li Y, Jin J, Wang Y. SIRT6 widely regulates aging, immunity, and cancer. *Front Oncol*. 2022;12:861334. <https://doi.org/10.3389/fonc.2022.861334>.
63. Wang X, Zhang P, Yan J, Huang J, Shen Y, He H, et al. SIRT6 deficiency impairs the deacetylation and ubiquitination of UHRF1 to strengthen glycolysis and lactate secretion in bladder cancer. *Cell Biosci*. 2024;14:153. <https://doi.org/10.1186/s13578-024-01333-2>.
64. You Q, Wang J, Yu Y, Li F, Meng L, Chen M, et al. The histone deacetylase SIRT6 promotes glycolysis through the HIF-1 α /HK2 signaling axis and induces erlotinib resistance in non-small cell lung cancer. *Apoptosis*. 2022;27:883–98. <https://doi.org/10.1007/s10495-022-01751-y>.
65. Fiorentino F, Carafa V, Favale G, Altucci L, Mai A, Rotili D. The two-faced role of SIRT6 in cancer. *Cancers (Basel)*. 2021. <https://doi.org/10.3390/cancers13051156>.
66. Cao Y, Wang S, Ma J, Long M, Ma X, Yang X, et al. Mechanistic insights into SIRT7 and EZH2 regulation of cisplatin resistance in bladder cancer cells. *Cell Death Dis*. 2024;15:931. <https://doi.org/10.1038/s41419-024-07321-1>.
67. Chen K, Li T, Diao H, Wang Q, Zhou X, Huang Z, et al. SIRT7 knockdown promotes gemcitabine sensitivity of pancreatic cancer cell via upregulation of GLUT3 expression. *Cancer Lett*. 2024;598:217109. <https://doi.org/10.1016/j.canlet.2024.217109>.
68. Geng Q, Peng H, Chen F, Luo R, Li R. High expression of Sirt7 served as a predictor of adverse outcome in breast cancer. *Int J Clin Exp Pathol*. 2015;8:1938–45.
69. Hu Z, Tang M, Huang Y, Cai B, Sun X, Chen G, et al. SIRT7 facilitates endometrial cancer progression by regulating PTEN stability in an estrogen-dependent manner.

- Nat Commun. 2025;16:2989. <https://doi.org/10.1038/s41467-025-58317-0>.
70. Huo Q, Chen S, Zhuang J, Quan C, Wang Y, Xie N. SIRT7 downregulation promotes breast cancer metastasis via LAP2alpha-induced chromosomal instability. *Int J Biol Sci*. 2023;19:1528–42. <https://doi.org/10.7150/ijbs.75340>.
 71. Kumari P, Tarighi S, Fuchshuber E, Li L, Fernandez-Duran I, Wang M, et al. SIRT7 promotes lung cancer progression by destabilizing the tumor suppressor ARF. *Proc Natl Acad Sci U S A*. 2024;121:e2409269121. <https://doi.org/10.1073/pnas.2409269121>.
 72. Paredes S, Villanova L, Chua KF. Molecular pathways: emerging roles of mammalian sirtuin SIRT7 in cancer. *Clin Cancer Res*. 2014;20:1741–6. <https://doi.org/10.1158/1078-0432.CCR-13-1547>.
 73. Shi X, Ji Y, Wu X, Du Y, Yan X, Wang Y, et al. Blocking of SIRT7/FOXO3a axis by miR-152-3p enhances cisplatin sensitivity in breast cancer. *Am J Med Sci*. 2025;369:105–15. <https://doi.org/10.1016/j.amjms.2024.08.028>.
 74. Tang M, Lu X, Zhang C, Du C, Cao L, Hou T, et al. Downregulation of SIRT7 by 5-fluorouracil induces radiosensitivity in human colorectal cancer. *Theranostics*. 2017;7:1346–59. <https://doi.org/10.7150/thno.18804>.
 75. Tang X, Shi L, Xie N, Liu Z, Qian M, Meng F, et al. SIRT7 antagonizes TGF-beta signaling and inhibits breast cancer metastasis. *Nat Commun*. 2017;8:318. <https://doi.org/10.1038/s41467-017-00396-9>.
 76. Tarighi S, Kumari P, Vaquero A, Braun T, Ianni A. The SIRT7-nucleolus connection in cancer: ARF enters the fray. *Mol Cell Oncol*. 2024;11:2381287. <https://doi.org/10.1080/23723556.2024.2381287>.
 77. Xu B, Cai X, Cai G, Huang G. SIRT7: a potential prognostic marker and therapeutic target in gallbladder cancer. *Pathol Res Pract*. 2024;256:155233. <https://doi.org/10.1016/j.prp.2024.155233>.
 78. Yang F, Hu Y, Shao L, Zhuang J, Huo Q, He S, et al. SIRT7 interacts with TEK (TIE2) to promote adriamycin induced metastasis in breast cancer. *Cell Oncol (Dordr)*. 2021;44:1405–24. <https://doi.org/10.1007/s13402-021-00649-2>.
 79. Yu H, Ye W, Wu J, Meng X, Liu RY, Ying X, et al. Overexpression of sirt7 exhibits oncogenic property and serves as a prognostic factor in colorectal cancer. *Clin Cancer Res*. 2014;20:3434–45. <https://doi.org/10.1158/1078-0432.CCR-13-2952>.
 80. Zhang S, Chen P, Huang Z, Hu X, Chen M, Hu S, et al. Sirt7 promotes gastric cancer growth and inhibits apoptosis by epigenetically inhibiting miR-34a. *Sci Rep*. 2015;5:9787. <https://doi.org/10.1038/srep09787>.
 81. Uzelac B, Krivokuca A, Brankovic-Magic M, Magic Z, Susnjar S, Milovanovic Z, et al. Expression of SIRT1, SIRT3 and SIRT6 genes for predicting survival in triple-negative and hormone receptor-positive subtypes of breast cancer. *Pathol Oncol Res*. 2020;26:2723–31. <https://doi.org/10.1007/s12253-020-00873-5>.
 82. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. *Nature*. 2000;406:747–52. <https://doi.org/10.1038/35021093>.
 83. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A*. 2001;98:10869–74. <https://doi.org/10.1073/pnas.191367098>.
 84. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. *J Clin Oncol*. 2009;27:1160–7. <https://doi.org/10.1200/JCO.2008.18.1370>.
 85. Gyorffy B. Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. *GeroScience*. 2023;45:1889–98. <https://doi.org/10.1007/s11357-023-00742-4>.
 86. Gyorffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. *Comput Struct Biotechnol J*. 2021;19:4101–9. <https://doi.org/10.1016/j.csbj.2021.07.014>.
 87. Gyorffy B. Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer. *Br J Pharmacol*. 2024;181:362–74. <https://doi.org/10.1111/bph.16257>.
 88. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J Roy Stat Soc: Ser B (Methodol)*. 1995;57:289–300.
 89. Menyhart O, Weltz B, Gyorffy B. Multiplereading.com: a tool for life science researchers for multiple hypothesis testing correction. *PLoS One*. 2021;16:e0245824. <https://doi.org/10.1371/journal.pone.0245824>.
 90. Bartha A, Gyorffy B. TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. *Int J Mol Sci*. 2021;22. <https://doi.org/10.3390/ijms22052622>.
 91. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. *Nature*. 2004;430:686–9.
 92. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. Small molecule activators of sirtuins extend *Saccharomyces cerevisiae* lifespan. *Nature*. 2003;425:191–6.
 93. Anderson RM, Bitterman KJ, Wood JG, Medvedik O, Sinclair DA. Nicotinamide and PNC1 govern lifespan extension by calorie restriction in *Saccharomyces cerevisiae*. *Nature*. 2003;423:181–5.
 94. Kobayashi Y, Furukawa-Hibi Y, Chen C, Horio Y, Isobe K, Ikeda K, et al. SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. *Int J Mol Med*. 2005;16:237–43.
 95. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. *Science*. 2004;303:2011–5.
 96. Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, et al. Nutrient-sensitive mitochondrial NAD⁺ levels dictate cell survival. *Cell*. 2007;130:1095–107. S0092-8674(07)00973-7 [pii].
 97. 1016/j.cell.2007.07.035
 98. Mao S, Ma J, Yu H. Sirtuin-7 knockdown inhibits the growth of endometrial cancer cells by inducing

- apoptosis via the NF- κ B signaling pathway. *Oncol Lett.* 2019;17:937–43. <https://doi.org/10.3892/ol.2018.9698>.
99. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Group M, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowitz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavaré S, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature.* 2012;486:346–352. <https://doi.org/10.1038/nature10983>
 100. Zulkifli ND, Zulkifle N. Insight from sirtuins interactome: topological prominence and multifaceted roles of SIRT1 in modulating immunity, aging and cancer. *Genomics Inform.* 2023;21:e23. <https://doi.org/10.5808/gi.23003>.
 101. Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. *Oncogene.* 2007;26:5489–504. <https://doi.org/10.1038/sj.onc.1210616>.
 102. Rodriguez RM, Fraga MF. Aging and cancer: are sirtuins the link? *Future Oncol.* 2010;6:905–15. <https://doi.org/10.2217/fon.10.57>.
 103. O'Callaghan C, Vassilopoulos A. Sirtuins at the crossroads of stemness, aging, and cancer. *Aging Cell.* 2017;16:1208–18. <https://doi.org/10.1111/accel.12685>.
 104. Kim HS, Xiao C, Wang RH, Lahusen T, Xu X, Vassilopoulos A, et al. Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. *Cell Metab.* 2010;12:224–36. <https://doi.org/10.1016/j.cmet.2010.06.009>.
 105. Kugel S, Sebastian C, Fitamant J, Ross KN, Saha SK, Jain E, et al. SIRT6 suppresses pancreatic cancer through control of Lin28b. *Cell.* 2016;165:1401–15. <https://doi.org/10.1016/j.cell.2016.04.033>.
 106. Park JJ, Hah YS, Ryu S, Cheon SY, Won SJ, Lee JS, et al. MDM2-dependent Sirt1 degradation is a prerequisite for Sirt6-mediated cell death in head and neck cancers. *Exp Mol Med.* 2021;53:422–31. <https://doi.org/10.1038/s12276-021-00578-y>.
 107. Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. *Cancer Cell.* 2008;14:312–23. <https://doi.org/10.1016/j.ccr.2008.09.001>.
 108. Ming M, Shea CR, Guo X, Li X, Soltani K, Han W, et al. Regulation of global genome nucleotide excision repair by SIRT1 through xeroderma pigmentosum C. *Proc Natl Acad Sci U S A.* 2010;107:22623–8. <https://doi.org/10.1073/pnas.1010377108>.
 109. Chalkiadaki A, Guarente L. The multifaceted functions of sirtuins in cancer. *Nat Rev Cancer.* 2015;15(10):608–24. <https://doi.org/10.1038/nrc3985>.
 110. Zhao E, Hou J, Ke X, Abbas MN, Kausar S, Zhang L, et al. The roles of sirtuin family proteins in cancer progression. *Cancers (Basel).* 2019. <https://doi.org/10.3390/cancers11121949>.
 111. Sun X, Wang S, Gai J, Guan J, Li J, Li Y, et al. SIRT5 promotes cisplatin resistance in ovarian cancer by suppressing DNA damage in a ROS-dependent manner via regulation of the Nrf2/HO-1 pathway. *Front Oncol.* 2019;9:754. <https://doi.org/10.3389/fonc.2019.00754>.
 112. Cimen H, Han MJ, Yang Y, Tong Q, Koc H, Koc EC. Regulation of succinate dehydrogenase activity by SIRT3 in mammalian mitochondria. *Biochemistry.* 2010;49:304–11. <https://doi.org/10.1021/bi901627u>.
 113. Chen Y, Zhang J, Lin Y, Lei Q, Guan KL, Zhao S, et al. Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. *EMBO Rep.* 2011;12:534–41. <https://doi.org/10.1038/embor.2011.65>.
 114. Torrens-Mas M, Oliver J, Roca P, Sastre-Serra J. SIRT3: oncogene and tumor suppressor in cancer. *Cancers (Basel).* 2017. <https://doi.org/10.3390/cancers9070090>.
 115. Locatelli M, Zoja C, Zanchi C, Corna D, Villa S, Bolognini S, et al. Manipulating sirtuin 3 pathway ameliorates renal damage in experimental diabetes. *Sci Rep.* 2020;10(1):8418. <https://doi.org/10.1038/s41598-020-65423-0>.
 116. Bell EL, Emerling BM, Ricoult SJ, Guarente L. Sirt3 suppresses hypoxia inducible factor 1 α and tumor growth by inhibiting mitochondrial ROS production. *Oncogene.* 2011;30:2986–96. <https://doi.org/10.1038/onc.2011.37>.
 117. Finley LW, Carracedo A, Lee J, Souza A, Egia A, Zhang J, et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1 α destabilization. *Cancer Cell.* 2011;19:416–28. <https://doi.org/10.1016/j.ccr.2011.02.014>.
 118. Xu L, Li Y, Zhou L, Dorfman RG, Liu L, Cai R, et al. SIRT3 elicited an anti-Warburg effect through HIF1 α -PDK1/PDHA1 to inhibit cholangiocarcinoma tumorigenesis. *Cancer Med.* 2019;8:2380–91. <https://doi.org/10.1002/cam4.2089>.
 119. Zou X, Zhu Y, Park SH, Liu G, O'Brien J, Jiang H, et al. SIRT3-mediated dimerization of IDH2 directs cancer cell metabolism and tumor growth. *Cancer Res.* 2017;77:3990–9. <https://doi.org/10.1158/0008-5472.CAN-16-2393>.
 120. Zhu Y, Yan Y, Principe DR, Zou X, Vassilopoulos A, Gius D. SIRT3 and SIRT4 are mitochondrial tumor suppressor proteins that connect mitochondrial metabolism and carcinogenesis. *Cancer Metab.* 2014;2:15. <https://doi.org/10.1186/2049-3002-2-15>.
 121. Kugel S, Feldman JL, Klein MA, Silberman DM, Sebastian C, Mermel C, et al. Identification of and molecular basis for SIRT6 loss-of-function point mutations in cancer. *Cell Rep.* 2015;13:479–88. <https://doi.org/10.1016/j.celrep.2015.09.022>.
 122. Chang AR, Ferrer CM, Mostoslavsky R. SIRT6, a mammalian deacetylase with multitasking abilities. *Physiol Rev.* 2020;100:145–69. <https://doi.org/10.1152/physrev.00030.2018>.
 123. Choe M, Brusgard JL, Chumsri S, Bhandary L, Zhao XF, Lu S, et al. The RUNX2 transcription factor negatively regulates SIRT6 expression to alter glucose metabolism in breast cancer cells. *J Cell Biochem.* 2015;116:2210–26. <https://doi.org/10.1002/jcb.25171>.
 124. Sebastian C, Zwaans BM, Silberman DM, Gymrek M, Goren A, Zhong L, et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism.

- Cell. 2012;151:1185–99. <https://doi.org/10.1016/j.cell.2012.10.047>.
125. Lu Y, Wang S, Jiao Y. The effects of deregulated ribosomal biogenesis in cancer. *Biomolecules*. 2023. <https://doi.org/10.3390/biom13111593>.
 126. Shang JL, Ning SB, Chen YY, Chen TX, Zhang J. MDL-800, an allosteric activator of SIRT6, suppresses proliferation and enhances EGFR-TKIs therapy in non-small cell lung cancer. *Acta Pharmacol Sin*. 2021;42:120–31. <https://doi.org/10.1038/s41401-020-0442-2>.
 127. Zhang S, Yang Y, Huang S, Deng C, Zhou S, Yang J, et al. SIRT1 inhibits gastric cancer proliferation and metastasis via STAT3/MMP-13 signaling. *J Cell Physiol*. 2019;234:15395–406. <https://doi.org/10.1002/jcp.28186>.
 128. Eroglu Z, Erdem C, Oktem G, Bozok Cetintas V, Duzgun Z. Effect of SIRT1 activators and inhibitors on CD44+/CD133+-enriched non-small cell lung cancer cells. *Mol Med Rep*. 2020;22:575–81. <https://doi.org/10.3892/mmr.2020.11113>.
 129. Gao Q, Yang L, Ye S, Mai M, Liu Y, Jiang X, et al. Targeting SIRT2 induces MLH1 deficiency and boosts anti-tumor immunity in preclinical colorectal cancer models. *Sci Transl Med*. 2025;17:eadv0766. <https://doi.org/10.1126/scitranslmed.adv0766>.
 130. Zou X, Santa-Maria CA, O'Brien J, Gius D, Zhu Y. Manganese superoxide dismutase acetylation and dysregulation, due to loss of SIRT3 activity, promote a luminal B-like breast carcinogenic-permissive phenotype. *Antioxid Redox Signal*. 2016;25:326–36. <https://doi.org/10.1089/ars.2016.6641>.
 131. Kumar S, Lombard DB. Mitochondrial sirtuins and their relationships with metabolic disease and cancer. *Antioxid Redox Signal*. 2015;22:1060–77. <https://doi.org/10.1089/ars.2014.6213>.
 132. Costa-Machado LF, Fernandez-Marcos PJ. The sirtuin family in cancer. *Cell Cycle*. 2019;18:2164–96. <https://doi.org/10.1080/15384101.2019.1634953>.
 133. Djouder N. Boosting NAD(+) for the prevention and treatment of liver cancer. *Mol Cell Oncol*. 2015;2:e1001199. <https://doi.org/10.1080/23723556.2014.1001199>.
 134. Xie N, Zhang L, Gao W, Huang C, Huber PE, Zhou X, et al. NAD(+) metabolism: pathophysiologic mechanisms and therapeutic potential. *Signal Transduct Target Ther*. 2020;5:227. <https://doi.org/10.1038/s41392-020-00311-7>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.